Biodexa Pharmaceuticals Plc
BDRX Nasdaq
SEC CIK 1643918
Follow Biodexa Pharmaceuticals
Weekly email: filings, results, news
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −£6.4M |
| FY24 | - | −£5.7M |
| FY23 | £381K | −£7.1M |
| FY22 | £699K | −£7.7M |
| FY21 | £578K | −£5.5M |
| FY20 | £343K | −£22.2M |
| FY19 | £674K | −£10.1M |
| FY18 | £1.9M | −£15M |
| FY17 | £989K | −£16.1M |
| FY16 | £1.3M | −£20.2M |
| FY15 | £1.4M | −£10.1M |
| FY14 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | - | - |
| FY24 | - | - | - |
| FY23 | - | −2103.4% | −1858% |
| FY22 | - | −1277.8% | −1095.3% |
| FY21 | - | −1210.7% | −944.6% |
| FY20 | - | −6717.2% | −6469.1% |
| FY19 | - | −1679.2% | −1496.3% |
| FY18 | - | −609.6% | −775.5% |
| FY17 | 674.6% | −1342.4% | −1624.3% |
| FY16 | 472.9% | −729.6% | −1524% |
| FY15 | 94.9% | −939.5% | −734.5% |
| FY14 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −£5.6M |
| FY24 | −£12.3M |
| FY23 | −£6.9M |
| FY22 | −£7.1M |
| FY21 | −£6.3M |
| FY20 | −£9.5M |
| FY19 | −£6.8M |
| FY18 | −£13.7M |
| FY17 | −£13.7M |
| FY16 | −£14.4M |
| FY15 | −£13.3M |
| FY14 | - |
- Biodexa Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Biodexa Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | - | −40.6% |
| FY24 | - | −60.7% |
| FY23 | −1858% | −97.1% |
| FY22 | −1095.3% | −128.5% |
| FY21 | −944.6% | −129.2% |
| FY20 | −6469.1% | −136.5% |
| FY19 | −1496.3% | −133.7% |
| FY18 | −775.5% | −173.4% |
| FY17 | −1624.3% | −176.7% |
| FY16 | −1524% | −164.8% |
| FY15 | −734.5% | −183.4% |
| FY14 | - | −133% |
News
No stories filed under Biodexa Pharmaceuticals yet - coverage appears here as the news feed clusters it.